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Summary
Endogenous hypercortisolism is associated with
an increased cardiovascular risk. Cushing Syn-
drome (CS) shares many clinical features with
metabolic syndrome, including abdominal obesity,
systemic arterial hypertension, insulin resistance,
dyslipidemia, and thrombotic diatesis. Moreover,
CS represents an interesting pattern of an en-
docrine disorder associated with chronic low-
grade inflammation which is not blunted by the
resolution of hypercortisolism. The proinflamma-
tory state that accompanies the metabolic syn-
drome may provide a connection between CS, in-
flammation and metabolic processes, which is
highly deleterious for vascular functions. There is
evidence that dietary patterns similar to those of
the Mediterranean-style diet exert positive effects
on almost all components of the metabolic syn-
drome and other conditions associated with, in-
cluding inflammation, insulin resistance, and en-
dothelial dysfunction. Therefore, an intervention
strategy based on lifestyle changes may play a
role in patients with resolution of hypercortisolism
in which the anti-inflammatory effects of cortisol
are lost and cytokines levels are increased. In this
setting, the Mediterranean healthy dietary pattern
may represent an innovative approach in order to
improve the disease course and to reduce in the
long term the cardiovascular risk of people affect-
ed by CS.
KEY WORDS: Cushing syndrome, metabolic syn-
drome, chronic low-grade inflammation, mediter-
ranean diet.
Introduction
Glucocorticoids are considered essential hormones
for life (1). Their levels raise up to ten times the nor-
mal values in stressing contexts, in order to provide
more blood and energy supply to cells and tissues (2,
3). Glucocorticoids also act as potent anti-inflammato-
ry agents stabilizing lysosomal membranes, inhibiting
prostaglandins and leukotrienes synthesis, blocking
the inflammatory response mediators and reducing
vascular permeability, chemotactic activity and leuko-
cycte diapedesis (4, 5). They also show immunosup-
pressor activity modulating lymphocyte, monocyte and
eosinophil biological action and inhibiting antibodies
production by B lymphocytes (6).
Cushing syndrome (CS) represents a clinical condition
produced by the chronic exposure to glucocorticoids
excess. The endogenous CS is caused by increased
cortisol secretion by adrenocortical tumors or hyper-
plasia  whereas the Cushing disease is usually sus-
tained by excessive ACTH release from a pituitary cor-
ticotrope adenoma (and less frequently by ectopic
ACTH or CRH production) (7, 8).  
Endogenous hypercortisolism is associated with an in-
creased cardiovascular risk. Untreated patients affect-
ed by CS undergo a fourfold mortality increase com-
pared with general population (9). Clinical features
linked to cardiovascular risk are visceral obesity, in-
sulin-resistance, impaired glucose tolerance (IGT) and
diabetes, hypertension, hyperlipidemia and pro-throm-
botic state (10). 
Adipose tissue is an endocrine organ producing differ-
ent cytokines involved in vascular inflammation, en-
dothelial dysfunction, insulin-resistance, hyperten-
sion, atherosclerosis, and bone remodeling (11). Each
clinical condition accompanied by visceral adiposity,
including CS, is characterized by an increased re-
lease of pro-inflammatory cytokines which are consid-
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ered as biomarkers of future cardiovascular disease.
In CS, the most important changes in cytokine milieu
refer to adiponectin, as well as TNF α, IL-6 and PAI-1
(12, 13).
Adiponectin is an adipocyte-derived plasma protein
with insulin sensitising, anti-inflammatory and anti-
atherogenic properties. In human studies, plasma
adiponectin levels are negatively correlated with
obesity, anthropometric indices and insulin resist-
ance, diabetic dyslipidaemia and cardiovascular dis-
ease (14, 15). Moreover, low plasma adiponectin
levels are an independent risk factor for future
development of type 2 diabetes (16). The findings
of an inverse correlation between adiponectin in-
crease and TNF- α decrease after weight loss in
obese women (17), seem to give some credit to the
hypothesis that raised TNF-a circulating levels in
obesity are causally linked to reduced adiponectin
concentrations. 
The role of adiponectin in CS is still unclear. Some ev-
idence suggests the dominant role of visceral adipos-
ity instead of hypercortisolism in reducing adiponectin
levels (12); on the other hand, low adiponectin levels
have been found in non obese patients with CS, sug-
gesting that hypercortisolism may impact adiponectin
levels, independent of body weight (18).
IL-6 is generally increased in patients with CS, al-
though its level may be influenced by the anti inflam-
matory effects of glucocorticoids. During the course of
the disease, fluctuations in IL-6 levels are observed,
as they are elevated in subclinical CS, decreased in
overt CS, increased during post-operatory hypocorti-
solism (19) and diminished in the course of replace-
ment therapy with corticosteroids (20). 
Although C-reactive protein (PCR) is not an adipokine,
its circulating concentrations are under the control of
adipokines and its role in inflammation is well defined.
Cross-sectional analyses have shown strong and in-
dependent associations of CRP levels with measures
of body fat (21, 22). High levels of CRP in obesity al-
so predict later development of diabetes (23).
CS represents an interesting pattern of an endocrine
disorder associated with metabolic abnormalities and
chronic low-grade inflammation which is not blunted
by the resolution of hypercortisolism. Paradoxically, in
the active phase of the disease, characterized by the
onset of the several associated comorbidities, such as
metabolic syndrome, diabetes and visceral obesity,
the increase in adipokines levels is partly hidden by
the potent anti-inflammatory effect played by cortisol.
Long term studies in patients who have suffered  from
CS show a persistent increased cardiovascular risk in
these individuals. Indeed, the accumulation of viscer-
al fat does not recede after treatment, with persistent-
ly elevated levels of pro-inflammatory cytokines (12).
It has been suggested that the persistence of the trunk
fat is an effect of cortisol excess on the omental adi-
pose tissue, stimulating the conversion of pre-
adipocytes in adipocytes, thus contributing to increase
of their number. Adipocyte hyperplasia also tends to
remain constant  even after the resolution of hypercor-
tisolism (12, 24-26).
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CS shares many clinical features with metabolic syn-
drome, including abdominal obesity, systemic arterial
hypertension, insulin resistance, dyslipidemia, and
thrombotic diatesis (10). The Adult Treatment Panel III
(ATP-III) guideline suggests a working definition of the
metabolic syndrome that includes the presence of at
least 3 of the following characteristics: waist circumfer-
ence > 102 cm in men and > 88 cm in women; triglyc-
erides >150 mg/dL; HDL < 40 mg/dL in men and < 50
mg/dL in women; blood pressure > 130/85 mmHg;
fasting glucose > 100 mg/dL (27). Insulin-resistance is
thought to be a key feature of the syndrome, that is
highly prognostic of cardiovascular events. Chronic in-
flammation may represent a triggering factor in the ori-
gin of the metabolic syndrome: stimuli such as overnu-
trition, physical inactivity, and ageing would result in
cytokine hypersecretion and eventually lead to insulin
resistance and diabetes in genetically or metabolically
predisposed individuals. All the parameters included in
the diagnosis of the metabolic syndrome are associat-
ed with a low-grade inflammation state (22, 28), which
in turn is associated with an increased cardiovascular
risk. The proinflammatory state that accompanies the
metabolic syndrome may provide a connection be-
tween CS, inflammation and metabolic processes,
which is highly deleterious for vascular functions. 
Diet and inflammation
Lifestyle interventions are the initial therapies recom-
mended for treatment of the metabolic syndrome (27).
Whereas each risk factor of the metabolic syndrome
(visceral obesity, atherogenetic dyslipidemia, elevated
blood pressure, and hyperglycemia) can be dealt indi-
vidually, the initial therapeutic approach to the meta-
bolic syndrome should focus on reversing its root
causes (29). In theory, the ideal diet should target
many, if not all, the dietary components thought to in-
fluence the cardiometabolic risk, including all types of
fat (saturated, polyunsaturated, monounsaturated,
and trans fats), fiber, fish, carbohydrates, and pro-
teins. There is evidence that dietary patterns similar to
those of the Mediterranean-style diet exert positive ef-
fects on almost all components of the metabolic syn-
drome and other conditions associated with, including
inflammation, insulin resistance, and endothelial dys-
function (30, 13).
Observational studies have examined the association
of the Mediterranean diet with inflammatory markers
in healthy persons (31-34), and they generally report
inverse correlations. In a subsample of the Nurses’
Health Study (33), a Mediterranean diet index score
was inversely associated with markers of inflamma-
tion (circulating IL-6 and CRP) as well as markers of
endothelial dysfunction (the adhesion molecules In-
tercellular Adhesion Molecule  1 [ICAM-1], Vascular
Cell Adhesion Molecule 1 [VCAM-1] and soluble E-se-
lectin [sE-selectin]). Similar findings were reported in
the ATTICA study (32), involving 1514 men and 1528
women: subjects with greater adherence to the
Mediterranean diet (those in the highest tertile) had
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17% lower IL-6 and 20% lower CRP concentrations,
compared with those in the lowest tertile in analyses
that adjusted for other cardiovascular risk factors. In
another observational study (34) made of obese sub-
jects (625 men and 712 women with abdominal adi-
posity), adoption of the Mediterranean diet in con-
junction with moderate physical activity was associat-
ed with a reduced likelihood of having high CRP lev-
els by 72%. 
Few intervention studies have been conducted to ex-
amine the effect of consuming the Mediterranean diet
on markers of low-grade inflammation. In a random-
ized controlled study with 120 pre-menopausal obese
women, the effects of a multidisciplinary approach
(aiming at 10% weight reduction with a combination of
a low-energy, Mediterranean-style diet and increased
physical activity) were evaluated compared with a
control group (17). Significant reduction in several
markers of inflammation (CRP, IL-6 and IL-18) and an
increase in adiponectin concentration were noted in
the Mediterranean diet group compared with the con-
trol group. In another randomized controlled trial last-
ing 2 years (35), 180 subjects with the metabolic syn-
drome were assigned either to a Mediterranean-style
diet or to a control group. After 2 years, inflammatory
markers (CRP, IL-6, IL-7 and IL-18) decreased and
endothelial function improved, compared with the con-
trol group. Interestingly, even after controlling for
weight loss, the inflammatory markers declined more
in subjects following the Mediterranean- style diet. In
other related studies involving individuals with the
metabolic syndrome, a consistent reduction in CRP
concentration in the intervention group receiving the
Mediterranean diet has been shown (36, 37). In the
Prevención con Dieta Mediterránea (predimed) study,
772 asymptomatic subjects at high cardiovascular risk
(diabetes or more than three CHD risk factors) were
randomly assigned to a low-fat diet or one of two
Mediterranean diets (38). Those allocated to the
Mediterranean diets received nutritional education
and either free virgin olive oil, or free nuts for 3
months. Both Mediterranean diets were beneficial in
terms of significant reductions in serum IL-6, sICAM-1
and sVCAM-1 concentrations, while CRP concentra-
tion was reduced only in the Mediterranean diet sup-
plemented with olive oil. 
Interestingly, a recent meta-analysis (39) of epidemio-
logical studies and randomized controlled trials con-
sidering a total of 534.906 participants showed that
Mediterranean diet was associated with reduced risk
or progression of metabolic syndrome. 
Taken together, the results from these studies suggest
that Mediterranean diets can lead to reduction in
chronic low-grade inflammation and improvement in
endothelial function.
Working hypothesis
CS is often associated with metabolic syndrome, vis-
ceral obesity and systemic low-grade inflammation,
presenting elevated circulating concentrations of many
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inflammatory markers that are believed to play a role
in causing both insulin resistance and other metabolic
disturbances. Several studies indicate that metabolic
syndrome generally persists after normalization of cor-
tisolemia in CS patient. Thus, treatment of CS is not al-
ways sufficient to remove metabolic syndrome and
specific approach for metabolic disturbances (high BP,
dyslipidemia, IGT and diabetes, obesity) has to be ad-
dressed. Blood concentrations of inflammatory mark-
ers are lowered following weight loss, whether this is
induced by diet or surgery, which most probably re-
flects the decrease in adipose tissue mass. A comple-
mentary role in reducing low-grade inflammation may
be obtained with physical exercise (17, 32). In addition
to the direct effect of foods and their constituents on
postprandial inflammation, diet has an impact on
chronic low-grade inflammation, manifested as the
basal (i.e. fasting state) concentrations of inflammato-
ry markers in the bloodstream, including cytokines,
chemokines, acute-phase proteins, soluble adhesion
molecules and cytokine receptors, etc. A healthy diet is
associated with decreased low grade inflammation; in
particular, protective components of a healthy dietary
pattern are considered whole grains, fiber, vegetables,
fruits, fish, Polyunsaturated Fatty Acids (PUFA), vita-
min C, vitamin E and carotenoids (40). A meta-analy-
sis comprising more than 1.5 million healthy subjects
followed for a time ranging from 3-18 years and 40,000
fatal and nonfatal events, shows that greater adher-
ence to Mediterranean diet is significantly associated
with a reduced risk of both overall and cardiovascular
mortality (41). Therefore, a healthy dietary pattern, as
Mediterranean diet is thought to be, may be an impor-
tant adjuvant treatment in improving the low-grade in-
flammation in overt CS. An intervention strategy based
on lifestyle changes may also play a role in patients
with resolution of hypercortisolism in which the anti-in-
flammatory effects of cortisol are lost and cytokines
levels are increased. In this setting, the Mediterranean
healthy dietary pattern may represent an innovative
approach in order to improve the disease course and
to reduce in the long term the cardiovascular risk of
people affected by CS. Future research should focus
on the long-term efficacy of this diet in people who suf-
fer from CS, associated or not with metabolic syn-
drome, even after the resolution of hypercortisolism.
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